
Ona Therapeutics moves to Phase I with ADC for advanced cancers
Ona Therapeutics has progressed to a Phase Ia clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers. The company says that more than half of the patients planned for the study have already been enrolled, with the trial continuing to… Read More
